Genmab — Juni 2018
-
Jeg føler ikke at markedeskræfter er frie...med den handlemåde ,,
-
Top five promising multiple myeloma research presented at ASCO 2018 https://www.myeloma.org/videos/top-five-promising-multiple-myeloma-research-presented-asco-2018-0
-
Synes ikke det ser ud som om AQR kommer til at score den store sum på Genmab.Godt nok er genmab faldet til ca. 1000kr men de sidste 6 mdr har været op - ned - sidelæns og så får AQR ikke det store ud af sin position. Dvs. hvis Genmab tager en sidelæns puster til næste optur, så får AQR intet ud af sin position. Så vil det koste at have positionen fordi det koster at låne aktier til at shorte. Med Maia og Europa 1st line på trapperne skal AQR da snart til at genvurdere deres Genmab.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind